CardioComm Solutions Announces Intention to Settle Outstanding Debt with Issuance of Shares

Toronto, Ontario--(Newsfile Corp. - July 25, 2025) - **CardioComm Solutions, Inc.** (TSXV: EKG) ("**CardioComm**" or the "**Company**"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("**ECG**") software solutions, announces that it has entered into debt settlement agreements with each of the directors of the Company, pursuant to which the Company will issue an aggregate of 4,162,500 common shares of the Company ("**Shares**") at a deemed price of $0.01 per Share to settle an aggregate of $41,625 in outstanding debt owed by the Company to the directors for services provided. When issued, the Shares will be subject to a four month hold period in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The debt settlement transactions and the issuance of the Shares thereunder is subject to receipt of approval from the TSX Venture Exchange.

The Company also announces that it has issued 250,000 stock options to Etienne Grima, the Company's CEO, in accordance with his employment agreement. The options are exercisable at $0.05 per share for five years from the date of grant and vest immediately. The grant is subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.

Each debt settlement transaction with a director, and the issuance of stock options to the Company's CEO, is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("**MI 61-101**"). Each transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of each transaction does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101.

To learn more about CardioComm's products and for further updates please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*).